Clinical trial
A Non-Randomized, Clinical Registry of the Dynamx Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients With De Novo Native Coronary Artery Lesions
NCT04483791 is registered in ClinicalTrials.gov with Elixir Medical Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-Randomized, Clinical Registry of the Dynamx Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients With De Novo Native Coronary Artery Lesions
- Lead sponsor
- Elixir Medical Corporation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 30, 2020
- Completion date
- December 31, 2022
- Enrollment
- 50 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.